Zenocutuzumab is a bispecific antibody targeting HER2 and HER3 preventing their combination in case of NRG1 fusion; it is currently assessed in a phase I/II trial including NSCLC with NRG fusion, with preliminary results showing a 35% ORR [247] (Table 11). The gene discussed is NRG1; the disease is non-small cell lung carcinoma.